“Big Pharma & Your Doctor” : Myths, Money, and Medicine
LISTEN ON APPLE PODCASTS | LISTEN ON SPOTIFY | LISTEN ON AMAZON MUSIC
A recent Vitals & Values clip went semi-viral after Dr. Lara stated plainly that doctors don't receive financial kickbacks for prescribing medications. The comment section disagreed loudly — golf clubs, quotas, the works. None of it was accurate, but the skepticism is real, and it deserves a real response.
This episode is that response. Dr. Lara and Dr. Jana Baatenburg join David to walk through what the relationship between physicians and pharmaceutical reps actually looks like at a concierge practice — what reps do, what they don't do, what's genuinely useful, what's a waste of everyone's time, and where the real lines are.
First, something most people don't know
In large hospital systems, pharmaceutical reps generally aren't allowed near physicians at all. Dr. Lara and Dr. Jana had almost zero interaction with pharma reps during their years in traditional primary care. An occasional signature for a continuous glucose monitor sample. That was it.
When you open your own practice, that changes fast. They find you. They show up with pamphlets, they want to set up lunches, and they want to tell you everything their medication can do. Learning how to manage that — who to see, when, and why — is something they've figured out through experience.
How they actually decide who gets in the door
The practice curates which reps they'll meet with. If it's a medication they don't prescribe and never would, the rep doesn't get a meeting. Simple as that. Time is finite, and sitting through a pitch for a medication that treats tardive dyskinesia — a movement disorder from long-term antipsychotic use — isn't a good use of a primary care physician's afternoon, no matter how many TV ads the drug is running.
For medications they do use regularly, it's a different calculation. There are genuine benefits to keeping those relationships going.
What pharma reps actually provide
The most concrete benefit is samples. When a patient needs to try an expensive medication — a GLP-1 for weight management, for instance, at close to $400 a month — being able to hand them a free month's supply so they can assess tolerability before committing to the cost is significant. It protects patients from spending money on something that doesn't work for them.
Reps also serve as a resource for insurance navigation. Which plans cover a medication? What's the prior authorization process? What needs to be coded a specific way to get it through? When they're dealing with a denial and trying to get a patient what they need, having someone on speed dial who knows the insurance landscape for their specific drug is legitimately useful.
New medications are another piece. Dr. Lara is clear that hearing about a new drug doesn't mean she'll prescribe it. But staying aware of what's available — particularly when something genuinely new comes to market — has value. She takes what reps present as a starting point, not a conclusion, and goes back to the clinical literature herself.
What it doesn't provide: influence over prescribing
Dr. Jana had a patient who was prescribed thyroid medication in her early 20s while trying to get pregnant. She'd been on it for nearly 20 years. When Dr. Jana had time to sit down and work through the full history, it became clear the medication had likely been prescribed in response to restrictive eating patterns — not Hashimoto's thyroiditis, which would have made it a lifelong medication. They stopped it. Her labs came back completely normal.
That kind of care — the digging, the revisiting, the questioning of what's always been — doesn't come from pharma influence. It comes from having enough time with a patient to actually think. And it works in the other direction too: plenty of patients actively want to stay on their medications. The goal isn't to get everyone off everything. The goal is the right decision for each person.
David ran the ProPublica numbers again for context. Over ten years, $12 billion in pharma gifts and incentives across 800,000 physicians. Forty-four percent of physicians received nothing. Of those who received anything, the average comes to about $51 per week — often split among the entire office staff, not just the physician. Most of the time, the doctor isn't even the one eating the lunch.
Separately, roughly 1% of physicians earn over $100,000 annually from pharma speaking and consulting arrangements. That's a different conversation — and one worth having — but it's not the same as being paid to prescribe.
Where the line actually is
The Purdue Pharma and OxyContin case gets brought up whenever this topic comes up, and it deserves to be taken seriously. What happened there was fraud — clinical data was manipulated, addiction risk was concealed, and some physicians operating pill mills lost their licenses and went to prison. That was a genuine catastrophe, and it happened because specific people did illegal things.
It's not an indictment of every pharmaceutical rep who shows up with coffee and pamphlets. The laws governing what reps can and can't do are stricter now than they were in the 1990s, when there were golf trips and dinners that would never pass compliance today. That tightening happened for a reason.
David is direct: if there's a specific, documented case of a physician receiving cash in exchange for prescribing a medication, he wants to hear about it. What he's not going to accept is the assumption that a Panera salad constitutes a bribe.
The stories that don't make it into the concern
There's a rep who keeps showing up with pamphlets for a new blood pressure medication. The pamphlets don't include the drug's name. Nobody knows why. They go in the recycling.
There was a period when multiple reps were bringing Crumble Cookies. The cookies are four dollars each. They're also enormous. Dr. Lara would like you to know that they can be cut into quarters.
Two reps for competing medications showed up at the same time once. Dr. Lara suspects this is partially why pharmaceuticals cost what they do.
The one dinner they ever attended — pushed and pressured for months by the Zepbound reps before Dr. Lara finally agreed, on the condition that it be nearby and immediately after work — was fine and informative, and something she will never do again. Spending time with pharma reps after hours, learning about medications she already knows enough about, isn't how she wants to spend her evenings.
There was also a technology rep who brought in a bioimpedance device and ran Dr. Lara through the assessment. Her BMI is 23. The device told her she was overweight and had POTS — a cardiovascular condition — and poor exercise capacity. None of that is accurate. They did not purchase the device. The rep went back to his company and reported that they needed to change how the system categorizes BMI.
What they'd actually change
Dr. Jana would drop all the paperwork. Nobody reads the pamphlets. They pile up and get thrown away. Save the trees, skip the binder.
Beyond that, the reps who are efficient, honest about what their medication does and doesn't do, and not trying to turn a five-minute conversation into a life story, those relationships work. The ones who oversell, cherry-pick data, or push dinners nobody asked for, those are easy to spot and easy to decline.
The practice's preference now is to support local restaurants when they do let reps bring lunch. If someone's going to bring food, it might as well go to a local business.
Vitals & Values is the podcast of Concierge Medicine of West Michigan, hosted by Dr. David Roden and Dr. Lara Baatenburg. New episodes available wherever you listen.
